Welch Group’s Krystal Biotech KRYS Stock Holding History

Welch Group’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$372K	Hold	1,000	–	–	0.01%	226
2026 Q1	$258K	Buy	+1,000	New	+$266K	0.01%	254

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Welch Group's KRYS Position: Q2 2026 in Review

Welch Group held its Krystal Biotech (KRYS) position steady in Q2 2026 at 1,000 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #226.

Welch Group first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Welch Group held 1,000 shares of Krystal Biotech worth $372K as of Q2 2026.
Welch Group left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up 0.01% of Welch Group's portfolio in Q2 2026, its #226 holding.
Welch Group first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Welch Group's 13F filing for Q2 2026, filed 23 Jul 2026.